The role of heat shock protein 70 (Hsp70) in radiation-induced immunomodulation

Cancer Letters

Volumn 368, Issue 2, 2015, Pages 179-184

  Multhoff, Gabriele ^a,b   Pockley, Alan G ^c   Schmid, Thomas E ^a   Schilling, Daniela ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

Heat shock proteins; Immunotherapy; Oncology; Radiation

Indexed keywords

HEAT SHOCK PROTEIN 70;

ADAPTIVE IMMUNITY; CELLULAR DISTRIBUTION; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SHORT SURVEY; SUPPRESSOR CELL; ANIMAL; BIOSYNTHESIS; IMMUNOLOGY; METABOLISM; NEOPLASMS; RADIATION RESPONSE; T LYMPHOCYTE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, RADIATION; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOMODULATION; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES;

EID: 84941880491     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.02.013     Document Type: Review

References (105)

1. Ritossa F.M. A new puffing pattern induced by temperature shock and DNP in Drosophila 1962, pp. 571-573.
2. Hartl F.U. Molecular chaperones in cellular protein folding. Nature 1996, 381:571-579.
3. Ellis S., Killender M., Anderson R.L. Heat-induced alterations in the localization of HSP72 and HSP73 as measured by indirect immunohistochemistry and immunogold electron microscopy. J. Histochem. Cytochem 2000, 48:321-332.
4. Seidberg N.A., Clark R.S., Zhang X., Lai Y., Chen M., Graham S.H., et al. Alterations in inducible 72-kDa heat shock protein and the chaperone cofactor BAG-1 in human brain after head injury. J. Neurochem 2003, 84:514-521.
5. Multhoff G., Botzler C., Jennen L., Schmidt J., Ellwart J., Issels R. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J. Immunol 1997, 158:4341-4350.
6. Vega V.L., Rodriguez-Silva M., Frey T., Gehrmann M., Diaz J.C., Steinem C., et al. Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. J. Immunol 2008, 180:4299-4307.
7. Ireland H.E., Leoni F., Altaie O., Birch C.S., Coleman R.C., Hunter-Lavin C., et al. Measuring the secretion of heat shock proteins from cells. Methods 2007, 43:176-183.
8. De Maio A. Heat shock proteins: facts, thoughts, and dreams. Shock 1999, 11:1-12.
9. Gehrmann M., Cervello M., Montalto G., Cappello F., Gulino A., Knape C., et al. Heat shock protein 70 serum levels differ significantly in patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Front. Immunol 2014, 5:307.
10. Nylandsted J., Gyrd-Hansen M., Danielewicz A., Fehrenbacher N., Lademann U., Hoyer-Hansen M., et al. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J. Exp. Med 2004, 200:425-435.
11. Gabai V.L., Yaglom J.A., Waldman T., Sherman M.Y. Heat shock protein Hsp72 controls oncogene-induced senescence pathways in cancer cells. Mol. Cell. Biol 2009, 29:559-569.
12. Garrido C., Brunet M., Didelot C., Zermati Y., Schmitt E., Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006, 5:2592-2601.
13. Calderwood S.K., Khaleque M.A., Sawyer D.B., Ciocca D.R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci 2006, 31:164-172.
14. Ciocca D.R., Arrigo A.P., Calderwood S.K. Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update. Arch. Toxicol 2013, 87:19-48.
15. Khaleque M.A., Bharti A., Gong J., Gray P.J., Sachdev V., Ciocca D.R., et al. Heat shock factor 1 represses estrogen-dependent transcription through association with MTA1. Oncogene 2008, 27:1886-1893.
16. Moseley P. Stress proteins and the immune response. Immunopharmacology 2000, 48:299-302.
17. Schmitt E., Gehrmann M., Brunet M., Multhoff G., Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J. Leukoc. Biol 2007, 81:15-27.
18. Srivastava P.K. Heat shock proteins in immune response to cancer: the Fourth Paradigm. Experientia 1994, 50:1054-1060.
19. Tesniere A., Panaretakis T., Kepp O., Apetoh L., Ghiringhelli F., Zitvogel L., et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008, 15:3-12.
20. Mayer M.P. Hsp70 chaperone dynamics and molecular mechanism. Trends Biochem. Sci 2013, 38:507-514.
21. Kim Y.E., Hipp M.S., Bracher A., Hayer-Hartl M., Hartl F.U. Molecular chaperone functions in protein folding and proteostasis. Annu. Rev. Biochem 2013, 82:323-355.
22. Multhoff G., Mizzen L., Winchester C.C., Milner C.M., Wenk S., Eissner G., et al. Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. Exp. Hematol 1999, 27:1627-1636.
23. Henderson B., Pockley A.G. Molecular chaperones and protein-folding catalysts as intercellular signaling regulators in immunity and inflammation. J. Leukoc. Biol 2010, 88:445-462.
24. Multhoff G., Pockley A.G., Streffer C., Gaipl U.S. Dual role of heat shock proteins (HSPs) in anti-tumor immunity. Curr. Mol. Med 2012, 12:1174-1182.
25. Guzhova I.V., Shevtsov M.A., Abkin S.V., Pankratova K.M., Margulis B.A. Intracellular and extracellular Hsp70 chaperone as a target for cancer therapy. Int. J. Hyperthermia 2013, 29:399-408.
26. De Maio A. Extracellular Hsp70: export and function. Curr. Protein Pept. Sci 2014, 15:225-231.
27. Gehrmann M., Liebisch G., Schmitz G., Anderson R., Steinem C., De M.A., et al. Tumor-specific Hsp70 plasma membrane localization is enabled by the glycosphingolipid Gb3. PLoS ONE 2008, 3:e1925.
28. Pomorski T., Holthuis J.C., Herrmann A., van Meer G. Tracking down lipid flippases and their biological functions. J. Cell Sci 2004, 117:805-813.
29. Schlegel R.A., Williamson P. Phosphatidylserine, a death knell. Cell Death Differ 2001, 8:551-563.
30. Tyurin V.A., Balasubramanian K., Winnica D., Tyurina Y.Y., Vikulina A.S., He R.R., et al. Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic "eat-me" signals: cleavage and inhibition of phagocytosis by Lp-PLA2. Cell Death Differ 2014, 21:825-835.
31. Segawa K., Suzuki J., Nagata S. Constitutive exposure of phosphatidylserine on viable cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:19246-19251.
32. Schilling D., Gehrmann M., Steinem C., De M.A., Pockley A.G., Abend M., et al. Binding of heat shock protein 70 to extracellular phosphatidylserine promotes killing of normoxic and hypoxic tumor cells. FASEB J. 2009, 23:2467-2477.
33. Fischer K., Voelkl S., Berger J., Andreesen R., Pomorski T., Mackensen A. Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells. Blood 2006, 108:4094-4101.
34. Srivastava P.K. New jobs for ancient chaperones. Sci. Am 2008, 299:50-55.
35. Weidle U.H., Maisel D., Klostermann S., Schiller C., Weiss E.H. Intracellular proteins displayed on the surface of tumor cells as targets for therapeutic intervention with antibody-related agents. Cancer Genomics Proteomics 2011, 8:49-63.
36. Calini V., Urani C., Camatini M. Overexpression of HSP70 is induced by ionizing radiation in C3H 10T1/2 cells and protects from DNA damage. Toxicol. In Vitro 2003, 17:561-566.
37. Gehrmann M., Brunner M., Pfister K., Reichle A., Kremmer E., Multhoff G. Differential up-regulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs. Clin. Cancer Res 2004, 10:3354-3364.
38. Stangl S., Gehrmann M., Riegger J., Kuhs K., Riederer I., Sievert W., et al. Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:733-738.
39. Hareyama M., Imai K., Ban T., Koshiba H., Kubo K., Shidou M., et al. Effect of radiation on the expression of carcinoembryonic antigen on the membranes of human gastric adenocarcinoma cells - immunological study using monoclonal antibodies. Nippon Igaku Hoshasen Gakkai Zasshi 1988, 48:1572-1574.
40. Gaugler M.H., Squiban C., Van Der M.A., Bertho J.M., Vandamme M., Mouthon M.A. Late and persistent up-regulation of intercellular adhesion molecule-1 (ICAM-1) expression by ionizing radiation in human endothelial cells in vitro. Int. J. Radiat. Biol 1997, 72:201-209.
41. Roses R.E., Datta J., Czerniecki B.J. Radiation as immunomodulator: implications for dendritic cell-based immunotherapy. Radiat. Res 2014, 182:211-218.
42. Wattenberg M.M., Fahim A., Ahmed M.M., Hodge J.W. Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy. Radiat. Res 2014, 10.1667/RR13374.1.
43. Garnett C.T., Palena C., Chakraborty M., Tsang K.Y., Schlom J., Hodge J.W. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004, 64:7985-7994.
44. Lanzavecchia A., Sallusto F. Antigen decoding by T lymphocytes: from synapses to fate determination. Nat. Immunol 2001, 2:487-492.
45. Muranski P., Restifo N.P. Essentials of Th17 cell commitment and plasticity. Blood 2013, 121:2402-2414.
46. Zhang H., Chua K.S., Guimond M., Kapoor V., Brown M.V., Fleisher T.A., et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat. Med 2005, 11:1238-1243.
47. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
48. Shin D.S., Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Curr. Opin. Immunol 2015, 33C:23-35.
49. Postow M.A., Callahan M.K., Wolchok J.D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol 2015, 10.1200/JCO.2014.59.4358.
50. Camacho L.H. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med 2015, 10.1002/cam4.371.
51. Emens L.A. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev. Anticancer Ther 2012, 12:1597-1611.
52. Caronni N., Savino B., Bonecchi R. Myeloid cells in cancer-related inflammation. Immunobiology 2015, 220:249-253.
53. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol 2005, 23:877-900.
54. Smyth M.J., Cretney E., Takeda K., Wiltrout R.H., Sedger L.M., Kayagaki N., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med 2001, 193:661-670.
55. Lakshmi Narendra B., Eshvendar Reddy K., Shantikumar S., Ramakrishna S. Immune system: a double-edged sword in cancer. Inflamm. Res 2013, 62:823-834.
56. Voskoboinik I., Dunstone M.A., Baran K., Whisstock J.C., Trapani J.A. Perforin: structure, function, and role in human immunopathology. Immunol. Rev 2010, 235:35-54.
57. Moretta L., Bottino C., Pende D., Vitale M., Mingari M.C., Moretta A. Human natural killer cells: molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol. Lett 2005, 100:7-13.
58. de Oliveira C.E., Oda J.M., Losi Guembarovski R., de Oliveira K.B., Ariza C.B., Neto J.S., et al. CC chemokine receptor 5: the interface of host immunity and cancer. Dis. Markers 2014, 2014:126954.
59. Weitzenfeld P., Ben-Baruch A. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett 2014, 352:36-53.
60. Ostrand-Rosenberg S., Sinha P., Chornoguz O., Ecker C. Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). Cancer Immunol. Immunother 2012, 61:1319-1325.
61. Ostrand-Rosenberg S., Horn L.A., Haile S.T. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J. Immunol 2014, 193:3835-3841.
62. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol 2001, 19:197-223.
63. Gross C., Schmidt-Wolf I.G., Nagaraj S., Gastpar R., Ellwart J., Kunz-Schughart L.A., et al. Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells. Cell Stress Chaperones 2003, 8:348-360.
64. Multhoff G., Botzler C., Issels R. The role of heat shock proteins in the stimulation of an immune response. Biol. Chem 1998, 379:295-300.
65. Multhoff G., Pfister K., Gehrmann M., Hantschel M., Gross C., Hafner M., et al. A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones 2001, 6:337-344.
66. Gastpar R., Gehrmann M., Bausero M.A., Asea A., Gross C., Schroeder J.A., et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res 2005, 65:5238-5247.
67. Gross C., Koelch W., DeMaio A., Arispe N., Multhoff G. Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J. Biol. Chem 2003, 278:41173-41181.
68. Gehrmann M., Stangl S., Kirschner A., Foulds G.A., Sievert W., Doss B.T., et al. Immunotherapeutic targeting of membrane hsp70-expressing tumors using recombinant human granzyme B. PLoS ONE 2012, 7:e41341.
69. Gehrmann M., Doss B.T., Wagner M., Zettlitz K.A., Kontermann R.E., Foulds G., et al. A novel expression and purification system for the production of enzymatic and biologically active human granzyme B. J. Immunol. Methods 2011, 371:8-17.
70. Moser C., Schmidbauer C., Gurtler U., Gross C., Gehrmann M., Thonigs G., et al. Inhibition of tumor growth in mice with severe combined immunodeficiency is mediated by heat shock protein 70 (Hsp70)-peptide-activated, CD94 positive natural killer cells. Cell Stress Chaperones 2002, 7:365-373.
71. Krause S.W., Gastpar R., Andreesen R., Gross C., Ullrich H., Thonigs G., et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin. Cancer Res 2004, 10:3699-3707.
72. Stangl S., Themelis G., Friedrich L., Ntziachristos V., Sarantopoulos A., Molls M., et al. Detection of irradiation-induced, membrane heat shock protein 70 (Hsp70) in mouse tumors using Hsp70 Fab fragment. Radiother. Oncol 2011, 99:313-316.
73. Stangl S., Wortmann A., Guertler U., Multhoff G. Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells. J. Immunol 2006, 176:6270-6276.
74. Bayer C., Liebhardt M.E., Schmid T.E., Trajkovic-Arsic M., Hube K., Specht H.M., et al. Validation of heat shock protein 70 as a tumor-specific biomarker for monitoring the outcome of radiation therapy in tumor mouse models. Int. J. Radiat. Oncol. Biol. Phys 2014, 88:694-700.
75. Srivastava P.K., Menoret A., Basu S., Binder R.J., McQuade K.L. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 1998, 8:657-665.
76. Binder R.J., Anderson K.M., Basu S., Srivastava P.K. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo. J. Immunol 2000, 165:6029-6035.
77. Binder R.J. Heat-shock protein-based vaccines for cancer and infectious disease. Expert Rev. Vaccines 2008, 7:383-393.
78. Tosti G., Cocorocchio E., Pennacchioli E., Ferrucci P.F., Testori A., Martinoli C. Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. Expert Opin. Biol. Ther 2014, 14:955-967.
79. Pilla L., Patuzzo R., Rivoltini L., Maio M., Pennacchioli E., Lamaj E., et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol. Immunother 2006, 55:958-968.
80. Mazzaferro V., Coppa J., Carrabba M.G., Rivoltini L., Schiavo M., Regalia E., et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res 2003, 9:3235-3245.
81. Srivastava P.K. Therapeutic cancer vaccines. Curr. Opin. Immunol 2006, 18:201-205.
82. Oki Y., McLaughlin P., Fayad L.E., Pro B., Mansfield P.F., Clayman G.L., et al. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 2007, 109:77-83.
83. Goloudina A.R., Demidov O.N., Garrido C. Inhibition of HSP70: a challenging anti-cancer strategy. Cancer Lett 2012, 325:117-124.
84. Rerole A.L., Gobbo J., De Thonel A., Schmitt E., Pais de Barros J.P., Hammann A., et al. Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res 2011, 71:484-495.
85. Sekihara K., Harashima N., Tongu M., Tamaki Y., Uchida N., Inomata T., et al. Pifithrin-mu, an inhibitor of heat-shock protein 70, can increase the antitumor effects of hyperthermia against human prostate cancer cells. PLoS ONE 2013, 8:e78772.
86. Schlecht R., Scholz S.R., Dahmen H., Wegener A., Sirrenberg C., Musil D., et al. Functional analysis of Hsp70 inhibitors. PLoS ONE 2013, 8:e78443.
87. Shevtsov M.A., Pozdnyakov A.V., Mikhrina A.L., Yakovleva L.Y., Nikolaev B.P., Dobrodumov A.V., et al. Effective immunotherapy of rat glioblastoma with prolonged intratumoral delivery of exogenous heat shock protein Hsp70. Int. J. Cancer 2014, 135:2118-2128.
88. Shevtsov M.A., Kim A.V., Samochernych K.A., Romanova I.V., Margulis B.A., Guzhova I.V., et al. Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children. Onco Targets Ther 2014, 7:1071-1081.
89. Sovik A., Malinen E., Skogmo H.K., Bentzen S.M., Bruland O.S., Olsen D.R. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Int. J. Radiat. Oncol. Biol. Phys 2007, 68:1496-1504.
90. Gray L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol 1953, 26:638-648.
91. Vaupel P., Kelleher D.K., Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol 2001, 28:29-35.
92. Molls M.V., Nieder P., Nieder C., Anscher M.S. The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies 2009, Springer, Berlin, Heidelberg.
93. Ran S., Thorpe P.E. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int. J. Radiat. Oncol. Biol. Phys 2002, 54:1479-1484.
94. Walton M., Sirimanne E., Reutelingsperger C., Williams C., Gluckman P., Dragunow M. Annexin V labels apoptotic neurons following hypoxia-ischemia. Neuroreport 1997, 8:3871-3875.
95. Hartl F.U., Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002, 295:1852-1858.
96. Ischia J., So A.I. The role of heat shock proteins in bladder cancer. Nat. Rev. Urol 2013, 10:386-395.
97. Barreto A., Gonzalez J.M., Kabingu E., Asea A., Fiorentino S. Stress-induced release of HSC70 from human tumors. Cell. Immunol 2003, 222:97-104.
98. Rubner Y., Muth C., Strnad A., Derer A., Sieber R., Buslei R., et al. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Radiat. Oncol 2014, 9:89.
99. Wang Y.S., Liu S.J., Huang S.C., Chang C.C., Huang Y.C., Fong W.L., et al. Recombinant heat shock protein 70 in combination with radiotherapy as a source of tumor antigens to improve dendritic cell immunotherapy. Front. Oncol 2012, 2:149.
100. Broquet A.H., Thomas G., Masliah J., Trugnan G., Bachelet M. Expression of the molecular chaperone Hsp70 in detergent-resistant microdomains correlates with its membrane delivery and release. J. Biol. Chem 2003, 278:21601-21606.
101. Guzhova I., Kislyakova K., Moskaliova O., Fridlanskaya I., Tytell M., Cheetham M., et al. In vitro studies show that Hsp70 can be released by glia and that exogenous Hsp70 can enhance neuronal stress tolerance. Brain Res 2001, 914:66-73.
102. Pockley A.G. Heat shock proteins as regulators of the immune response. Lancet 2003, 362:469-476.
103. Asea A., Ara G., Teicher B.A., Stevenson M.A., Calderwood S.K. Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo. Int. J. Hyperthermia 2001, 17:347-356.
104. Bausero M.A., Gastpar R., Multhoff G., Asea A. Alternative mechanism by which IFN-gamma enhances tumor recognition: active release of heat shock protein 72. J. Immunol 2005, 175:2900-2912.
105. Devaux P.F. Static and dynamic lipid asymmetry in cell membranes. Biochemistry 1991, 30:1163-1173.